Stockscreener 앱 받기
1.43
3.38%
-0.05
전일 마감가:
$1.48
열려 있는:
$1.53
하루 거래량:
8,028
Relative Volume:
0.21
시가총액:
$159.73M
수익:
$3.13M
순이익/손실:
$-55.77M
주가수익비율:
-2.3271
EPS:
-0.6145
순현금흐름:
$-61.24M
1주 성능:
-11.73%
1개월 성능:
-28.86%
6개월 성능:
-11.73%
1년 성능:
-33.18%
1일 변동 폭
$1.43
$1.53
1주일 범위
$1.42
$1.58
52주 변동 폭
$1.17
$2.71
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.43 | 159.73M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-11 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2025-09-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | 개시 | BTIG Research | Buy |
| 2021-09-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 개시 | Goldman | Neutral |
모두보기
Innate Pharma Adr 주식(IPHA)의 최신 뉴스
Innate Pharma (IPHA) Edges Lower to $1.51 as ADS Holds Near the Middle of Its RangeTPO Profile - https://www.siam.in/
Innate Pharma S.A. (IPH.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA) - Zacks Investment Research
Innate Pharma S.A. (IPHA) stock price, news, quote and history - Yahoo Finance Australia
Innate Pharma S.A. (IPHA) stock price, news, quote and history - Yahoo Finance UK
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track? - Yahoo Finance
Innate Pharma S.A. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IPHA) 2026-09-22 - Seeking Alpha
Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip By Investing.com - Investing.com South Africa
Innate Pharma Q2 Earnings Call Highlights - Yahoo Finance
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update - Yahoo Finance
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Innate Pharma S.A. ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Nyxoah SA (NYXH) Stock Price & News - Syfe
Innate Pharma S.A. ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Innate (IPHA) Q1 2026 Earnings: EPS Comes in Below Forecast under the Current Snapshot; Trading Response: Shares Move 2.95% Higher in the Latest ReadingConsensus Beat Rate - dars.gov.et
Innate (IPHA) Q1 2026 Earnings: EPS Comes in Below Forecast under the Current Snapshot; Trading Response: Shares Move 2.95% Higher in the Latest ReadingTangible Book Value - careplusvn.com
Innate (IPHA) Results Check: EPS Comes in Below Forecast under the Current Snapshot; Closing Move: Shares Rise 8.13% in Latest TradingGAAP Earnings Report - careplusvn.com
Innate (IPHA) Results Check: EPS Comes in Below Forecast under the Current Snapshot; Closing Move: Shares Rise 8.13% in Latest TradingEarnings Miss Streak - dars.gov.et
Innate (IPHA) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Move: The Market Price Moves 2.42% Higher at the CloseFinancial Summary - careplusvn.com
Innate (IPHA) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Move: The Market Price Moves 2.42% Higher at the CloseHigh Estimate Range - dars.gov.et
Innate (IPHA) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Move - dars.gov.et
Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ... - Yahoo Finance
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - sharewise.com
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - Yahoo Finance
Innate Pharma Announces Conference Call and Webcast - Business Wire
Innate Pharma (IPHA) Tumbles 14% to $2.18: Support Test LoomsSkew Index - careplusvn.com
Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares - Business Wire
Innate Pharma (IPHA) Edges Higher by 2.63% to $2.54, Testing Mid-Range Trading BandLeveraged ETF Flow - careplusvn.com
Innate Pharma (IPHA) Edges Higher by 2.63% to $2.54, Testing Mid-Range Trading BandDealer Delta - dars.gov.et
Innate Pharma (IPHA) Edges Higher by 2.63% to $2.54, Testing Mid-Range Trading BandUp Down Ratio - dars.gov.et
Innate Pharma Announces Proposed Offering of Ordinary Shares - Business Wire
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
FY2026 EPS Estimates for Innate Pharma Reduced by Analyst - MarketBeat
Innate Pharma (IPHA) Rallies 14.9% to $2.47, Faces Key Resistance at $2.59Gap Down Bounce Plays - dars.gov.et
Innate Pharma (IPHA) Rallies 14.9% to $2.47, Faces Key Resistance at $2.59MA Cross Alert - www.dars.gov.et
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com South Africa
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com India
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer - Business Wire
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy - Benzinga
IPHA Stock Firms Up As IPH4502 Trial Hits Key Milestone - stockstotrade.com
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - businesswire.com
Innate Pharma (IPHA) Surges 28.3% to $2.22 as Biotech Sentiment StrengthensLow Vol ETF - dars.gov.et
Innate Pharma plans phase 3 trial, names new medical officer - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com India
Innate Pharma partners with Sobi on lacutamab development - Investing.com
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com South Africa
IPHA Q1 2026 Earnings: Wider-than-Expected Loss, Shares Edge HigherRetail Earnings Report - careplusvn.com
Innate Pharma Adr (IPHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):